Neurosense Therapeutics Ltd Stock Price, News & Analysis

NeuroSense Therapeutics (NASDAQ: NRSN) has partnered with NeuraLight to enhance the identification and tracking of digital biomarkers for ALS using AI and machine learning. The collaboration aims to share patient data to improve monitoring of ALS, a severe neurodegenerative disease affecting over 5,000 new patients annually in the U.S. NeuroSense is currently conducting a Phase IIb trial for its lead drug candidate, PrimeC, which has already shown promise in earlier studies.

NeuroSense Therapeutics (Nasdaq: NRSN) provided a corporate update concerning its lead drug candidate, PrimeC, aimed at treating ALS. Two clinical studies launched in Q2 2022, including a Phase IIb trial assessing PrimeC’s efficacy involving 69 ALS patients across Israel, Italy, and the US, with results expected in Q2 2023. A biomarker study indicated PrimeC's potential, while a study on Alzheimer's drug candidate, CogniC, will begin in 2023. The firm focuses on addressing severe neurodegenerative diseases, emphasizing the need for effective therapies.

SpyBiotech has appointed Mark Leuchtenberger as CEO, expanding its leadership team and establishing a U.S. presence with a new office in Cambridge, Massachusetts. Leuchtenberger, with over 20 years in the biopharmaceutical sector, aims to advance the company's proprietary vaccine technology that utilizes SpyTag/SpyCatcher protein superglue. The firm plans to initiate clinical studies for its lead candidate targeting human cytomegalovirus (HCMV) in 2023. The company has raised $39 million to date, including a $32.5 million Series A financing last year.

NeuroSense Therapeutics (NASDAQ: NRSN) announced promising results from its biomarker study for CogniC, a combination drug aimed at treating Alzheimer's disease (AD). The study identified biomarkers indicating CogniC's potential effectiveness in addressing AD pathways, such as miRNA dysregulation and lysosomal dysfunction. High levels of TDP-43 were noted in AD patients, spotlighting its role in the disease. NeuroSense plans to initiate a proof-of-concept clinical trial in 2023, utilizing innovative Neuron-Derived Exosomes technology for biomarker assessment.

NeuroSense Therapeutics (NASDAQ: NRSN) announced encouraging preliminary results from Stage III of its ALS biomarker study, showing that standard care patients had stable disease-related biomarker levels. In contrast, patients treated with PrimeC, NeuroSense's lead drug candidate, demonstrated a significant decline in these biomarkers during the Phase IIa study. The study validates NeuroSense's clinical strategy and aims to optimize a pivotal Phase III study of PrimeC. NeuroSense's approach to ALS treatment is bolstered by collaborations with Massachusetts General Hospital, focusing on innovative biomarkers.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) will participate in a panel discussion on ALS innovations on June 28, 2022. Co-founder and CEO Alon Ben-Noon will join experts to discuss ALS treatments. The company is currently enrolling participants for its Phase IIb clinical trial, PARADIGM, testing its lead drug candidate, PrimeC, in Israel, Italy, and the USA, with topline results expected in Q2 2023. PrimeC, a combination of ciprofloxacin and celecoxib, received Orphan Drug Designation for targeting ALS. The unmet needs in ALS therapies underscore the significance of this discussion.

NeuroSense Therapeutics (Nasdaq: NRSN) announced the enrollment of the first patient in its Phase IIb PARADIGM trial for PrimeC, aimed at treating amyotrophic lateral sclerosis (ALS). The trial, which will include 69 participants from Israel, Italy, and the U.S., is designed to assess ALS-related biomarkers and clinical efficacy. PrimeC, a combination of ciprofloxacin and celecoxib, has FDA and EMA Orphan Drug Designation. Previous Phase IIa results showed significant efficacy, including reduced respiratory deterioration. Top-line results from PARADIGM are expected by Q2 2023.

NeuroSense Therapeutics (NASDAQ: NRSN) reported Q1 2022 financial results, revealing a cash position of $13.74 million, up from $11.06 million in Q4 2021. The net loss increased to $2.71 million from $2.12 million in Q1 2021, primarily due to heightened general and administrative expenses. Notably, the company initiated biomarker studies for ALS and Alzheimer's, received FDA clearance for its IND application for PrimeC, and commenced a pharmacokinetic study. Looking ahead, a Phase IIb ALS clinical trial is set to begin in Q2 2022, with results anticipated in Q3.

NeuroSense Therapeutics (Nasdaq: NRSN) announces that Dr. Ferenc Tracik will present at the ALS Drug Development Summit on May 26, 2022, in Boston. The focus will be on the company's Phase IIb study, PARADIGM, that aims to evaluate the combination therapy PrimeC in treating ALS. The presentation will cover the design and findings of earlier trials, emphasizing the significance of ALS biomarkers for regulatory approval. NeuroSense is progressing towards a Phase IIb trial scheduled for Q2 2022, targeting ALS disease progression and aiming to enhance patient quality of life.